×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease T
clinical
1,930 words
KG: Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
parkinsons
csf1r
microglia
neuroinflammation
pexidartinib
phase2
Contents
Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)
Knowledge Graph
Related Hypotheses (22)
TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming
Score: 0.59
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.58
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE-TREM2 Interaction Modulation
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
APOE Isoform Conversion Therapy
Score: 0.44
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
Show 17 more
Related Analyses (17)
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 12 more
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
Show 25 more
Knowledge Graph (3 edges)
Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)
references
APOE
Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)
references
NLRP3
Pexidartinib (PLX3397) CSF1R Inhibitor Parkinson's Disease Trial (NCT04888966)
references
TREM2